Results 71 to 80 of about 80,955 (206)

Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation

Journal of Bone Oncology, 2019
Chondrosarcoma is a malignant tumor that arises from cartilaginous tissue and is radioresistant and chemoresistant to conventional treatments. The preferred treatment consists of surgical resection, which might cause severe disabilities for the patient ...
Mathieu Césaire, Utpal Ghosh, Jean-Baptiste Austry, Etienne Muller, Francesco Paolo Cammarata, Marilyne Guillamin, Massimo Caruso, Laurent Castéra, Giada Petringa, Giuseppe Antonio Pablo Cirrone, François Chevalier   +10 more
doaj   +1 more source

In vitro analysis of PARP inhibitor nanoformulations

, 2018
Paige Baldwin,1 Shifalika Tangutoori,1,2 Srinivas Sridhar1,2 1Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA; 2Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA Abstract: PARP-l is a ...
Sridhar S, Tangutoori S, Baldwin P
core  

MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling

Current Issues in Molecular Biology
Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in homologous recombination (HR) but show limited and heterogeneous efficacy in non-small-cell lung cancer (NSCLC), where canonical HR deficiency is uncommon. Identifying alternative molecular
Ramazan Gundogdu
doaj   +1 more source

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

, 2015
Hongying Sui, Caixia Shi, Zhipeng Yan, Hucheng LiDepartment of Gynecological Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha City, People’s Republic of ...
Li H, Yan Z, Shi C, Sui H
core  

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Frontiers in Immunology
ObjectiveSeveral clinical trials have explored the efficacy and safety of Poly (ADP-ribose) polymerase (PARP) inhibitors in endometrial cancer (EC). However, evidence supporting PARP inhibitors alone or in combination with other medications in advanced ...
Huanhuan Zhang, Huanhuan Zhang, Guangwei Yan, Guangwei Yan, Jinxiang Yan, Jinxiang Yan, Xianxu Zeng, Xianxu Zeng   +7 more
doaj   +1 more source

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

, 2019
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaAbstract: Poly (ADP-ribose) polymerase (PARP) inhibitors
Li W, Li X, Zhang Z, Jiang X, Bai H
core  

BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS [PDF]

, 2016
In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality ...
Esposito, Maria Teresa
core  

Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors

Nature Communications
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied.
Carmen R. Moncayo, Restuadi Restuadi, Guanying Zhang, Daniel Marks, Paula Ortega-Prieto, Emily Doherty, Nathalie Lambie, Chad Whilding, Ivan Andrew, Alex Montoya, Bhavik Patel, Katie Tyson, Betheney R. Pennycook, Lauren Pendergast, Vincen Wu, Zoltan Takats, Nik Matthews, George R. Young, Priyanka Verma, Pavel Shliaha, Laurence Game, Boris Lenhard, Iain McNeish, Christina Fotopoulou, Alexis R. Barr, Paula Cunnea, Zoe Hall, Louise Fets   +27 more
doaj   +1 more source

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

PLoS ONE, 2018
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging.
Z Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Jake Moscarelli, Amy Xiong, Yasmin Korayem, Pamela H Huang, Smith Giri, Patricia LoRusso, Elena S Ratner   +9 more
doaj   +1 more source

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer

, 2018
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada Abstract: Rucaparib is a potent small-molecule inhibitor of poly (ADP ...
Colombo I, Oza AM, Lheureux S
core